Before the development of modern vaccines, societies across Asia, Africa, and Europe practiced variolation, a method of inoculation intended to confer immunity against smallpox. Documented in China by the 15th and 16th centuries, variolation involved introducing dried scabs or fluid from smallpox pustules into the skin or nasal passages of healthy individuals.¹³ Although variolation generally produced a milder case of the disease than natural infection, it carried the risk of triggering full-scale smallpox epidemics or killing the recipient. The English writer Lady Mary Wortley Montagu observed the practice in the Ottoman Empire and introduced it to Britain in 1721.

The transition to safer immunization began in 1796 with the English physician Edward Jenner. Observing that dairymaids who contracted cowpox—a mild disease affecting cattle—appeared protected against smallpox, Jenner inoculated an eight-year-old boy, James Phipps, with matter taken from a cowpox lesion. When Jenner later exposed the boy to smallpox, Phipps did not develop the illness. Because the immunizing material originated from cows, the procedure became known as vaccination, derived from vacca, the Latin word for cow. By 1840, the British government had banned variolation and provided smallpox vaccination free of charge.

Nearly a century later, the French chemist and microbiologist Louis Pasteur expanded the principle of vaccination beyond smallpox. In 1880, Pasteur demonstrated that aged, weakened cultures of bacteria could immunize chickens against fowl cholera. He subsequently developed an anthrax vaccine for livestock and, in 1885, successfully prevented rabies in a human patient using a series of post-exposure injections prepared from dried spinal cord tissue of infected rabbits. To honor Jenner, Pasteur proposed that the term vaccine be extended to cover all immunizing preparations.

In the 1890s, researchers discovered that immunity against certain bacteria could be induced using chemically inactivated bacterial toxins, known as toxoids, leading to effective treatments and preventives for diphtheria and tetanus.¹⁴ The 20th century saw rapid expansion in viral and bacterial cultivation techniques. Vaccines against pertussis (whooping cough) and yellow fever were introduced in the 1930s, followed by the first influenza vaccines in the 1940s. In the 1950s, Jonas Salk developed an inactivated poliomyelitis vaccine using virus grown in monkey kidney cells, and Albert Sabin followed with an oral live-attenuated polio vaccine approved in 1960.¹⁵ During the mid-to-late 20th century, the American microbiologist Maurice Hilleman at Merck & Co. developed more than 40 experimental and licensed vaccines, including eight on the routine childhood immunization schedule: measles, mumps, rubella (combined into the MMR shot), chickenpox (varicella), hepatitis A, hepatitis B, pneumococcus, and meningococcus.^16171819

In the late 20th and early 21st centuries, advances in molecular genetics transformed vaccine design. The introduction of the recombinant hepatitis B vaccine in 1986 replaced blood-derived antigens with viral surface proteins produced in genetically modified yeast. Decades of foundational research by biochemists Katalin Karikó and Drew Weissman into nucleoside modifications—which prevent synthetic messenger RNA from triggering severe inflammatory reactions—enabled the deployment of mRNA vaccines during the COVID-19 pandemic in 2020.

Vaccines operate by training the human immune system to recognize and combat specific pathogens before natural infection occurs. Pathogenic bacteria, viruses, and parasites carry distinct molecular structures on their surfaces, primarily proteins or complex sugars called polysaccharides. When introduced into the body, these foreign structures act as antigens, triggering an immune cascade.

Upon administration—most commonly via intramuscular or subcutaneous injection, though some formulations are delivered orally or intranasally—the vaccine's antigens are detected by the innate immune system.²⁰ Specialized immune cells, including macrophages and dendritic cells known as antigen-presenting cells, engulf the vaccine antigen, break it down into smaller peptide fragments, and display these fragments on their exterior surfaces. These cells then migrate to the lymph nodes, where they activate the adaptive immune system.

The adaptive response relies on two major classes of white blood cells: B lymphocytes and T lymphocytes. Helper T cells recognize the presented antigen and release chemical signals that stimulate B cells to proliferate and mature into plasma cells. These plasma cells secrete large quantities of antibodies—specialized proteins engineered to bind specifically to the pathogen's antigen, neutralizing the microbe and marking it for destruction by other immune cells. Simultaneously, cytotoxic T cells are trained to identify and destroy human cells that have already been infected by the pathogen, preventing the microbe from replicating.

Once the simulated infection is cleared, most of the effector immune cells die off, leaving behind a population of long-lived memory B cells and memory T cells. During a natural exposure to an infectious agent in an unvaccinated individual, the adaptive immune system typically requires days or weeks to mount a primary response, allowing the pathogen time to multiply and cause severe or fatal illness. In a vaccinated individual, the pre-existing memory cells recognize the pathogen immediately and mount a secondary immune response, producing antibodies and killer T cells rapidly enough to prevent the infection from establishing itself or to substantially reduce the severity of the resulting disease.

Beyond protecting the immunized individual, widespread vaccination generates herd immunity, also called community immunity.²¹ When a high proportion of a population is immune to a contagious disease, chains of person-to-person transmission are disrupted.²² This reduces the likelihood that susceptible individuals—such as newborn infants too young to be vaccinated, pregnant women, or people with compromised immune systems from chemotherapy or organ transplants—will encounter the pathogen. The proportion of a population that must be immune to halt endemic transmission, known as the herd immunity threshold, depends on the pathogen's basic reproduction number ($R_0$), which measures the average number of secondary infections caused by a single infected host in a wholly susceptible population.²³²⁴ Polio requires an immunization threshold of roughly 80 percent, whereas measles, one of the most contagious known human viruses with an $R_0$ between 12 and 18, requires 95 percent coverage to prevent sustained outbreaks. Herd immunity does not apply to non-contagious infectious diseases such as tetanus, where the bacterium enters the body through environmental contamination of wounds rather than human transmission.

Scientists classify vaccines according to the biological method used to prepare the antigen or deliver genetic instructions to the host's cells. The choice of platform depends on the nature of the pathogen, how the immune system responds to it, and the demographic profile of the target population.

In addition to the active antigen or genetic material, a liquid or freeze-dried vaccine vial contains several excipients designed to ensure potency, stability, and sterility throughout its shelf life.²⁶ Water or physiological saline makes up the bulk of most injectable preparations.

Adjuvants are pharmacological or immunological substances added to many inactivated, subunit, and toxoid vaccines to amplify and prolong the recipient's immune response.²⁷ Because highly purified protein antigens lack the natural molecular danger signals present on whole microbes, they often fail to provoke a sufficient immune reaction on their own.²⁸²⁹ Adjuvants stimulate the innate immune system at the injection site, recruiting antigen-presenting cells and allowing manufacturers to use smaller quantities of antigen per dose. Aluminum salts—specifically aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate—have been used as human vaccine adjuvants since the 1930s. Newer adjuvant systems incorporate squalene oil-in-water emulsions or synthetic molecules that target specific cellular receptors to enhance immunity in older adults or against complex pathogens like malaria and shingles. Because adjuvants intentionally heighten local inflammation, adjuvanted vaccines more frequently cause temporary soreness, redness, swelling at the injection site, and mild fever.

Stabilizers, including sugars (such as sucrose and lactose), amino acids (such as glycine), and proteins (such as gelatin or human serum albumin), protect the active ingredients from chemical degradation caused by freeze-drying or temperature fluctuations during transport. Preservatives are added to multi-dose vials to prevent the growth of dangerous bacteria or fungi that could be introduced when a healthcare worker repeatedly pierces the rubber stopper with a syringe needle. The most historically prominent preservative is thiomersal (known in the United States as thimerosal), an ethylmercury-containing compound; single-dose vials generally do not contain preservatives unless required during the manufacturing process. Finally, finished vaccines may contain trace amounts of manufacturing residuals—measured in parts per million or parts per billion—such as formaldehyde (used to inactivate viruses and toxins), antibiotics like neomycin (used to prevent bacterial contamination of cell cultures), or egg and yeast proteins from the growth medium.

The development of a new human vaccine from initial laboratory discovery to regulatory licensure typically takes a decade or more and follows a standardized international sequence of preclinical and clinical evaluation.³⁰ During the exploratory and preclinical stages, academic and pharmaceutical researchers identify natural or synthetic antigens and test candidate formulations in tissue-culture systems and laboratory animals, such as mice, ferrets, or non-human primates.³¹ These studies assess potential toxicity, determine safe starting dosages, and verify that the candidate elicits an immune response capable of protecting the animal against a challenge with the pathogen.

If preclinical tests succeed, the sponsor submits an application—such as an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) or an equivalent dossier to the European Medicines Agency (EMA)—outlining manufacturing protocols and animal data to gain authorization for human testing. Human clinical trials proceed through three sequential pre-licensure phases.

In Phase I trials, the candidate vaccine is administered to a small group of healthy adult volunteers, typically between 20 and 80 people, to evaluate basic safety, identify common side effects, and confirm that the formulation induces an immune response. If no severe safety signals emerge, the vaccine advances to Phase II trials, which enroll several hundred participants (typically 100 to 300) whose demographic and health characteristics match the intended target population.³² Phase II studies are often randomized and controlled, testing various dose strengths and immunization schedules to establish optimal immunogenicity and gather broader safety data.

Phase III trials expand testing to thousands or tens of thousands of volunteers across multiple clinical and geographic sites. These trials are almost always randomized, double-blind, and placebo-controlled: participants are assigned by chance to receive either the experimental vaccine or a saline placebo (or an existing comparator vaccine), with neither the volunteers nor the investigators knowing who received which injection until the study concludes. Phase III trials measure vaccine efficacy—the percentage reduction in disease incidence among the vaccinated group compared to the unvaccinated group under trial conditions—and are large enough to detect rare adverse events.

Upon successful completion of Phase III, the manufacturer submits a Biologics License Application (BLA) or marketing authorization request containing hundreds of thousands of pages of clinical and chemical data. Regulatory scientists inspect the manufacturing facilities and review every batch (lot) release protocol to ensure purity, sterility, and consistency. Following licensure, vaccines enter Phase IV, a period of ongoing post-marketing surveillance. Because clinical trials cannot detect extremely rare side effects that occur in one out of every several hundred thousand doses, public health agencies and the World Health Organization (WHO) monitor real-world safety and long-term effectiveness across millions of recipients through passive reporting databases and active epidemiological tracking.

Immunization is widely documented by epidemiologists as one of the most cost-effective public health interventions in history.³³ Through coordinated global vaccination campaigns, humanity has permanently eradicated two major infectious diseases.³⁴ Following an intensified worldwide surveillance and ring-vaccination effort led by the WHO, smallpox—which killed hundreds of millions of people over centuries—was declared eradicated in 1980. In 2011, the Food and Agriculture Organization (FAO) and the World Organisation for Animal Health (OIE) declared the global eradication of rinderpest, a viral cattle plague that had caused devastating famines across Africa and Eurasia, achieved through widespread use of the attenuated RBOK vaccine.³⁵

In 1974, building on the momentum of the smallpox campaign, the WHO established the Expanded Programme on Immunization (EPI) to ensure universal childhood access to routine vaccines. Initially targeting six childhood diseases—tuberculosis, diphtheria, tetanus, pertussis, poliomyelitis, and measles—the program expanded to cover 14 priority pathogens, adding protection against hepatitis B, Haemophilus influenzae type b, rubella, rotavirus, pneumococcal disease, Japanese encephalitis, meningitis A, and yellow fever.³⁶ According to a 2024 modeling study published in The Lancet, vaccines administered under the EPI prevented at least 154 million deaths during its first 50 years, gaining 10.2 billion years of full health globally. Measles vaccination alone accounted for 60 percent of that total, saving nearly 94 million lives, while polio immunization prevented paralysis in more than 20 million people and eliminated wild poliovirus transmission from almost all regions of the world.³⁷³⁸

The global vaccine industry generated approximately $35 billion in annual revenue during 2024 and 2025.³⁹ Development and high-value sales are concentrated among multinational pharmaceutical corporations including GSK, Pfizer, Sanofi, and Merck & Co., while high-volume manufacturing for low- and middle-income nations relies heavily on producers in India and China, such as the Serum Institute of India and Sinopharm. International procurement and equitable distribution are coordinated by UNICEF and Gavi, the Vaccine Alliance, a public-private partnership founded in 2000.⁴⁰ In the 2020s, the global portfolio expanded to include the first licensed vaccines against respiratory syncytial virus (RSV) and malaria (such as the R21/Matrix-M vaccine).

Despite its scientific record, vaccination has generated public controversy and organized opposition since its inception. In the 19th century, mandatory smallpox vaccination laws in the United Kingdom and the United States provoked resistance from citizens and anti-vaccination leagues who viewed compulsory inoculation as an infringement on personal liberty, bodily autonomy, or religious beliefs.

In the late 20th and early 21st centuries, vaccine hesitancy—defined as the delay in acceptance or refusal of vaccines despite the availability of immunization services—was heavily influenced by a 1998 paper published in the British medical journal The Lancet by Andrew Wakefield and twelve co-authors.⁴¹⁴² Based on a small case series of twelve children, Wakefield suggested that the combined MMR vaccine was linked to gastrointestinal inflammation and the onset of developmental regression and autism. Although subsequent large-scale epidemiological studies involving millions of children reviewed by the Institute of Medicine, the Centers for Disease Control and Prevention (CDC), the WHO, and the Cochrane Library found no link between the MMR vaccine and autism, media coverage of Wakefield's claim caused MMR uptake in Britain to drop from 92 percent in 1995 to 84 percent in 2002, triggering measles outbreaks.⁴³⁴⁴ Investigative reporting by journalist Brian Deer later revealed that Wakefield had falsified patient data, subjected children to unethical invasive procedures, and received more than £400,000 in undisclosed payments from lawyers suing vaccine manufacturers.⁴⁵ Ten of the co-authors retracted the paper's interpretation in 2004, The Lancet fully retracted the study as fraudulent in February 2010, and Britain's General Medical Council revoked Wakefield's medical license. Separate public concerns in the late 1990s regarding the mercury-based preservative thiomersal also prompted precautionary removal of the compound from most routine childhood vaccines in the United States and Europe, even though toxicological and epidemiological reviews found no evidence of harm aside from minor local hypersensitivity.

During and after the COVID-19 pandemic, public trust in immunization declined across numerous countries, driven by debates over government vaccine mandates, political polarization, and the rapid spread of health misinformation on digital platforms. Surveys by the Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine documented falling confidence in vaccine safety between 2015 and 2024 across multiple regions. In the United States, Kaiser Family Foundation data from 2025 indicated that 16 percent of parents had skipped or delayed at least one routine childhood shot, and one-third of adults had encountered the false claim that the MMR vaccine is more dangerous than measles itself, up from 18 percent in 2024.⁴⁶ Amid policy shifts that included an executive order by President Donald Trump recommending changes to the childhood immunization schedule, the United States recorded more confirmed measles cases in 2026 than in any year since the disease was declared eliminated nationally in 2000.

Globally, structural barriers such as armed conflict, population displacement, poverty, and fragile cold-chain infrastructure continue to limit immunization reach. According to the WHO-UNICEF Estimates of National Immunization Coverage released in July 2026, 90 percent of infants worldwide (nearly 116 million) received at least one dose of the diphtheria, tetanus, and pertussis (DTP) vaccine in 2025, and 85 percent (110 million) completed all three doses. However, an estimated 13.5 million "zero-dose" children received no vaccines at all during their first year of life, and another 7.3 million infants dropped out after their initial DTP shot before receiving a measles vaccine. Consequently, global measles coverage in 2025 stood at 84 percent for the first dose and 77 percent for the second—well below the 95 percent herd immunity threshold—resulting in large or disruptive measles outbreaks across 57 countries.